876-04-0

Basic information

• Product Name: (R)-Octopamine
• Synonyms: (R)-2-Amino-1-(4-hydroxyphenyl)ethanol;(R)-Octopamine;(R)-α-(Aminomethyl)-p-hydroxybenzyl alcohol;[R,(-)]-α-(Aminomethyl)-4-hydroxybenzyl alcohol;4-[(R)-1-Hydroxy-2-aminoethyl]phenol
• CAS NO: 876-04-0
• Molecular Formula: C₈H₁₁NO₂
• Molecular Weight: 0
• Mol File: 876-04-0.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (R)-Octopamine(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-Octopamine(876-04-0)
• EPA Substance Registry System: (R)-Octopamine(876-04-0)

Safety Data

• Hazardous Substances Data: 876-04-0(Hazardous Substances Data)

Upstream product

• 104-14-3 octopamine 
• 473552-22-6 (R)-(-)-2-azido-1-(4-benzyloxyphenyl)-1-ethanol 
• 123-08-0 4-hydroxy-benzaldehyde 
• 56-40-6 glycine 
• 77943-99-8 (R)-2-(4-hydroxyphenyl)-2-hydroxyacetonitrile 
• 831171-92-7 [2-hydroxy-2-(4-hydroxy-phenyl)-ethyl]-carbamic acid 9H-fluoren-9-ylmethyl ester 
• 851714-32-4 [(R)-2-hydroxy-2-(4-acetoxy-phenyl)-ethyl]-carbamic acid benzyl ester 
• 473552-31-7 (R)-1-(4-benzyloxyphenyl)-2-(p-tolylsulfonyloxy)ethanol 
• 2628-17-3 4-Vinylphenol 

Relevant articles and documents

Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia

Ulotaront (SEP-363856) is a trace-amine associated receptor 1 (TAAR1) agonist with 5-HT1A receptor agonist activity in Phase 3 clinical development, with FDA Breakthrough Therapy Designation, for the treatment of schizophrenia. TAAR1 is a G-protein-coupled receptor (GPCR) that is expressed in cortical, limbic, and midbrain monoaminergic regions. It is activated by endogenous trace amines, and is believed to play an important role in modulating dopaminergic, serotonergic, and glutamatergic circuitry. TAAR1 agonism data are reported herein for ulotaront and its analogues in comparison to endogenous TAAR1 agonists. In addition, a human TAAR1 homology model was built around ulotaront to identify key interactions and attempt to better understand the scaffold-specific TAAR1 agonism structure-activity relationships.

Synthesis of aromatic 1,2-amino alcohols utilizing a bienzymatic dynamic kinetic asymmetric transformation

The applicability of the recent published bienzymatic protocol for the synthesis of (R)-2-amino-1-phenylethanol was tested using L-threonine aldolase from Pseudomonas putida and L-tyrosine decarboxylase from either Enterococcus faecalis (Efa) or two genes from Enterococcus faecium (Efil, Efi2). In all 21 benzaldehyde derivatives were applied for an initial TLC screening. On a small scale, octopamine and noradrenaline were obtained as (S)-enantiomers using Efil. Three protocols were upscaled yielding enantioenriched (S)-octopamine (yield 99%, ee 81%), (R)-2-amino-1-phenylethanol (yield 61%, ee 62%) and (S)-noradrenaline (yield 76%, ee 79%).

COMPOUNDS AND METHODS FOR TREATMENT OF CANCER AND MODULATION OF PROGRAMMED CELL DEATH FOR MELANOMA AND OTHER CANCER CELLS

Compounds and related methods for synthesis, and the use of compounds and combination therapies for the treatment of cancer and modulation of apoptosis in cells are disclosed. The generation of synthetic combinatorial libraries and the evaluation of library member compounds regarding induction of apoptosis selectively in cancer cells are disclosed. Compounds, methods of making the compounds, and therapeutic methods with application against breast cancer cells, melanoma cancer cells, colon cancer cells, and other cancer cells are described.